Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition

📆 28/07/2023 8:48 p. m.
📰 Forbes

⏱ Reading Time:
15 sec. here
2 min. at publisher
📊 Quality Score:
News: 9%
Publisher: 53%

Colombia Noticias Noticias

Colombia Últimas Noticias,Colombia Titulares

Biogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.

Biogen will pay $172.50 per share in cash for Reata, which had a Thursday closing price of $108.

55), andThe company was founded in Plano, Texas in 2002 and focuses on antioxidative and anti-inflammatory drugsBiogen, a Massachusetts-based biotech company with a market cap of nearly $38 billion, has acquired three other companies in the last eight years. The $200 million

Escribir Comentario

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

Colombia Últimas Noticias, Colombia Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion AcquisitionBiogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.
Fuente: Forbes - 🏆 394. / 53 Leer más »

Biogen to bulk up rare disease treatments with $7 billion Reata acquisitionBiogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments.
Fuente: WashTimes - 🏆 235. / 63 Leer más »